DEAL with Obesity Act of 2024

[Congressional Bills 118th Congress] [From the U.S. Government Publishing Office] [H.R. 10272 Introduced in House (IH)] <DOC> 118th CONGRESS 2d Session H. R. 10272 To amend title XVIII of the Social Security Act to provide coverage of weight loss agents for certain individuals under part D of the Medicare program. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES December 3, 2024 Mrs. Cherfilus-McCormick (for herself and Mr. Kelly of Pennsylvania) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend title XVIII of the Social Security Act to provide coverage of weight loss agents for certain individuals under part D of the Medicare program. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Dual Eligible Americans Living with Obesity Act of 2024'' or the ``DEAL with Obesity Act of 2024''. SEC. 2. FINDINGS. Congress finds the following: (1) According to the Kaiser Family Foundation, 12.5 million people are dually enrolled in both Medicare and Medicaid. (2) Dual Eligible beneficiaries overwhelmingly possess limited financial resources, with 87 percent having an income of less than $20,000 annually. (3) A one month's supply of a GLP-1 receptor agonist, on average, costs between $900 and $1,350. (4) Coverage of GLP-1 medications can lower out-of-pocket monthly costs to as little as $25 per month, according to a study published in JAMA. (5) Data from the Centers for Medicare and Medicaid show that 38 percent of Medicaid beneficiaries and 48 percent of Medicare benef